Abstract
There are controversial about the application of cancer-directed surgery (CDS) in patients with liver metastases from gastric cancer, with improved responses to chemotherapy and targeted treatments, the role of CDS in metastatic gastric cancer to the liver needs to be revisited. This study aimed to evaluate the effect of CDS on patients with liver metastases from gastric cancer. Data for patients with liver metastases from gastric cancer were extracted from the population-based Surveillance, Epidemiology, and End Results (SEER) database. A total of 958 individuals were enrolled, 285 in the CDS group and 673 in the non-cancer guided surgery (Non-CDS) group. Following propensity score matching (PSM) analysis at 1:1 in the two groups,285 were included in the survival analysis for each group. Kaplan–Meier values and Cox proportional risk models were used to estimate the effect of CDS on patients' prognoses. Compared with the Non-CDS group, the CDS group significantly prolonged the median overall survival from 4 months (95% confidence interval [CI] 3–5) to 11 months (95% CI 8–12), p value < 0.001. Overall survival (OS) at 1 year was higher in the CDS group than in the Non-CDS group, at 44% (95 CI 38–50) and 25% (95 CI 20–30), respectively. OS at 3 years was also higher in the CDS group than in the Non-CDS group, at 24% (95 CI 19–29) and 6% (95 CI 3–9), respectively. Multivariate analysis showed that Non-CDS (hazard ratio[HR] = 2.26, 95% CI 1.88–2.72, p value < 0.001) was an adverse independent prognostic factor for patients. This study concludes that CDS prolonged survival in patients with gastric cancer with liver metastases. Due to the lack of information on the quality of life, biomarkers, targeted therapies, and immunotherapy in the SEER database, the observed improved survival rates following CDS of hepatic metastasis from gastric cancer requires prospective studies that take these factors into account to properly address the survival advantages and impact on quality of life of such a method.
Similar content being viewed by others
Data availability
The data sets generated during and/or analyzed during the current study are available from SEER.
References
Thrift AP, El-Serag HB. Burden of gastric cancer. Clin Gastroenterol Hepatol. 2020;18:534–42. https://doi.org/10.1016/j.cgh.2019.07.045.
Machlowska J, Baj J, Sitarz M, Maciejewski R, Sitarz R. Gastric cancer: epidemiology, risk factors, classification, genomic characteristics and treatment strategies. Int J Mol Sci. 2020;21:4012. https://doi.org/10.3390/ijms21114012.
Ilic M, Ilic I. Epidemiology of stomach cancer. World J Gastroenterol. 2022;28:1187–203. https://doi.org/10.3748/wjg.v28.i12.1187.
Sexton RE, Al Hallak MN, Diab M, Azmi AS. Gastric cancer: a comprehensive review of current and future treatment strategies. Cancer Metastasis Rev. 2020;39:1179–203. https://doi.org/10.1007/s10555-020-09925-3.
Smyth EC, Nilsson M, Grabsch HI, van Grieken NC, Lordick F. Gastric cancer. Lancet (London, England). 2020;396:635–48. https://doi.org/10.1016/S0140-6736(20)31288-5.
Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2018 (5th edition). Gastric Cancer. 2021;24:1–21. https://doi.org/10.1007/s10120-020-01042-y.
Ajani JA, D’Amico TA, Bentrem DJ, Chao J, Cooke D, Corvera C, et al. Gastric cancer, version 2.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw JNCCN. 2022;20:167–92. https://doi.org/10.6004/jnccn.2022.0008.
Lordick F, Carneiro F, Cascinu S, Fleitas T, Haustermans K, Piessen G, et al. Gastric cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33:1005–20. https://doi.org/10.1016/j.annonc.2022.07.004.
Zhang KC, Wang PP, Chen L. Surgical teratment for gastric cancer patients with liver metastasis. Zhonghua Zhong Liu Za Zhi [Chin J Oncol]. 2019;41:183–6. https://doi.org/10.3760/cma.j.issn.0253-3766.2019.03.005.
Li S-C, Lee C-H, Hung C-L, Wu J-C, Chen J-H. Surgical resection of metachronous hepatic metastases from gastric cancer improves long-term survival: a population-based study. PLoS ONE. 2017;12:e0182255. https://doi.org/10.1371/journal.pone.0182255.
Aurello P, Minervini A, Pace M, D’Angelo F, Nigri G, Antolino L, et al. The role of surgery in the treatment of metachronous liver metastasis from gastric cancer: a systematic review. Anticancer Res. 2022;42:25–33. https://doi.org/10.21873/anticanres.15453.
Picado O, Dygert L, Macedo FI, Franceschi D, Sleeman D, Livingstone AS, et al. The role of surgical resection for stage IV gastric cancer with synchronous hepatic metastasis. J Surg Res. 2018;232:422–9. https://doi.org/10.1016/j.jss.2018.06.067.
Xiao Y, Zhang B, Wu Y. Prognostic analysis and liver metastases relevant factors after gastric and hepatic surgical treatment in gastric cancer patients with metachronous liver metastases: a population-based study. Ir J Med Sci. 2019;188:415–24. https://doi.org/10.1007/s11845-018-1864-4.
Arigami T, Matsushita D, Okubo K, Kawasaki Y, Iino S, Sasaki K, et al. Indication and prognostic significance of conversion surgery in patients with liver metastasis from gastric cancer. Oncology. 2020;98:273–9. https://doi.org/10.1159/000505555.
Zheng M, Li Y, Li T, Zhang L, Zhou L. Resection of the primary tumor improves survival in patients with gastro-entero-pancreatic neuroendocrine neoplasms with liver metastases: a SEER-based analysis. Cancer Med. 2019;8:5128–36. https://doi.org/10.1002/cam4.2431.
Kamarajah SK, Markar SR, Phillips AW, Salti GI, Dahdaleh F, Griffiths EA. Palliative gastrectomy for metastatic gastric adenocarcinoma: a national population-based cohort study. Surgery. 2021;170:1702–10. https://doi.org/10.1016/j.surg.2021.07.016.
Granieri S, Altomare M, Bruno F, Paleino S, Bonomi A, Germini A, et al. Surgical treatment of gastric cancer liver metastases: systematic review and meta-analysis of long-term outcomes and prognostic factors. Crit Rev Oncol Hematol. 2021;163:103313. https://doi.org/10.1016/j.critrevonc.2021.103313.
Ikari N, Taniguchi K, Serizawa A, Yamada T, Yamamoto M, Furukawa T. A primary tumor of mixed histological type is a novel poor prognostic factor for patients undergoing resection of liver metastasis from gastric cancer. J Hepatobiliary Pancreat Sci. 2017;24:281–8. https://doi.org/10.1002/jhbp.445.
Yamaguchi T, Kashu N, Yasuda K, Yoshitake H, Takami T, Hatano K, et al. Two cases of advanced gastric cancer with simultaneous liver metastasis with long-term recurrence-free survival. Gan to Kagaku Ryoho Cancer Chemotherapy. 2019;46:2333–5 (PMID: 32156922).
Ozato Y, Kawabata R, Furukawa H, Shinno N, Sueda T, Matsumura T, et al. A case of long-term survival without recurrence following resection of hepatic and pulmonary metastases of gastric cancer. Gan to Kagaku Ryoho Cancer Chemotherapy. 2019;46:580–2 (PMID: 30914620).
Kawahara K, Makino H, Kametaka H, Hoshino I, Fukada T, Seike K, et al. Outcomes of surgical resection for gastric cancer liver metastases: a retrospective analysis. World J Surg Oncol. 2020;18:41. https://doi.org/10.1186/s12957-020-01816-9.
Shirasu H, Tsushima T, Kawahira M, Kawai S, Kawakami T, Kito Y, et al. Role of hepatectomy in gastric cancer with multiple liver-limited metastases. Gastric Cancer. 2018;21:338–44. https://doi.org/10.1007/s10120-017-0730-9.
Li Y, Xie D, Chen X, Hu T, Lu S, Han Y. Prognostic value of the site of distant metastasis and surgical interventions in metastatic gastric cancer: a population-based study. Technol Cancer Res T. 2020;19:1533033820964131. https://doi.org/10.1177/1533033820964131.
Jeong S-A, Yoo M-W, Lee I-S, Gong CS, Ko CS, Jheong JH, et al. Comparing surgical and oncologic outcomes between laparoscopic gastrectomy and open gastrectomy in advanced gastric cancer with serosal invasion: a retrospective study with propensity score matching. Eur J Surg Oncol. 2022;48:1988–93. https://doi.org/10.1016/j.ejso.2022.05.019.
Xie Y, Song X, Dong W, Jin H, Ni Z, Li X, et al. Anatomic subsites and prognosis of gastric signet ring cell carcinoma: a SEER population-based 1: 1 propensity-matched study. Biomed Res Int. 2022;2022:1565207. https://doi.org/10.1155/2022/1565207.
Dias AR, Pereira MA, Ramos MFKP, Barchi LC, Ribeiro U, Zilberstein B, et al. Gastrectomy for elderly gastric cancer patients: a propensity score-matching analysis. J Surg Oncol. 2022;126:108–15. https://doi.org/10.1002/jso.26850.
Pausch TM, Liu X, Cui J, Wei J, Miao Y, Heger U, et al. Survival benefit of resection surgery for pancreatic ductal adenocarcinoma with liver metastases: a propensity score-matched SEER database analysis. Cancers. 2021;14:57. https://doi.org/10.3390/cancers14010057.
Omari J, Drewes R, Orthmer M, Hass P, Pech M, Powerski M. Treatment of metastatic gastric adenocarcinoma with image-guided high-dose rate, interstitial brachytherapy as second-line or salvage therapy. Diagn Interv Radiol (Ankara, Turkey). 2019;25:360–7. https://doi.org/10.5152/dir.2019.18390.
Yamaguchi H, Honda M, Hamada K, Kobayashi H, Todate Y, Seto I, et al. The effectiveness of proton beam therapy for liver metastatic recurrence in gastric cancer patients. Jpn J Clin Oncol. 2020;50:903–8. https://doi.org/10.1093/jjco/hyaa052.
Akamaru Y, Wada N, Adachi S, Hokkoku D, Eguchi S, Wada R, et al. Two cases of liver metastasis from gastric cancer achieving long-term survival successfully treated with stereotactic body radiotherapy (SBRT). Gan to Kagaku Ryoho Cancer Chemotherapy. 2019;46:2110–2.
Li K, Zhang A, Li X, Zhang H, Zhao L. Advances in clinical immunotherapy for gastric cancer. Biochim Biophys Acta Rev Cancer. 2021;1876:188615. https://doi.org/10.1016/j.bbcan.2021.188615.
Fujitani K, Kurokawa Y, Takeno A, Kawabata R, Omori T, Imamura H, et al. Prospective multicenter interventional study of surgical resection for liver metastasis from gastric cancer: R0 resection rate, and operative morbidity and mortality. Ann Surg Oncol. 2022;29:924–32. https://doi.org/10.1245/s10434-021-10750-3.
Shan B, Shan L, Morris D, Golani S, Saxena A. Systematic review on quality of life outcomes after gastrectomy for gastric carcinoma. J Gastrointest Oncol. 2015;6:544–60. https://doi.org/10.3978/j.issn.2078-6891.2015.046.
Acknowledgements
This work was supported by the Hainan Province's Key Research and Development Project (No. ZDYF2021SHFZ234), the Research Project of Hainan Provincial Health Commission (No. 22A200071), the Hainan Provincial Natural Science Foundation Youth Fund Funding Project (No. 819QN364), and the Funds of Talent Recruitment and Development of The Second Affiliated Hospital of Hainan Medical University.
Author information
Authors and Affiliations
Contributions
All authors contributed to the study's conception and design. Material preparation, data collection, and analysis were performed by NNJ, WT, XWW, and RL. The first draft of the manuscript was written by NNJ. Statistical analysis: QC, ZHL and YCZ, and all authors commented on previous versions of the manuscript and approved the final manuscript.
Corresponding authors
Ethics declarations
Conflict of interest
The authors declare that there are no conflicts of interest.
Ethical approval and informed consent
This study has been approved by the Ethics Committee of The Second Affiliated Hospital of Hainan Medical University. The access to and use of SEER data did not require informed patient consent.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Ji, NN., Wu, XW., Cao, Q. et al. Influence of cancer-directed surgery on the prognosis of liver metastases from gastric cancer. Clin Transl Oncol 26, 756–764 (2024). https://doi.org/10.1007/s12094-023-03305-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12094-023-03305-3